Product Description
Bumetanide belongs to a group of medicines called loop diuretics or "water pills." Bumetanide is given to help treat fluid retention (edema) and swelling that is caused by congestive heart failure, liver disease, kidney disease, or other medical conditions. It works by acting on the kidneys to increase the flow of urine . (Sourced from: https://www.mayoclinic.org/drugs-supplements/bumetanide-oral-route/description/drg-20071274)
Mechanisms of Action: NKCC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Canada | Chile | China | Colombia | Cyprus | Denmark | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | India | Ireland | Italy | Jordan | Lebanon | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Serbia | Singapore | Slovenia | South Africa | Spain | Sweden | Taiwan | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Autism Spectrum Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BAMBI | P2 |
Active, not recruiting |
Autism Spectrum Disorder |
2019-04-07 |